01
Nature-inspired
Inspired by naturally regenerative human tissues, known for their ability to support healing and restore damaged environments.
Regenerative therapies · Buenos Aires
New generation technologies in regenerative therapies.
An injectable, birth-tissue based therapy to regenerate the heart after a myocardial infarction and prevent heart failure.
Backed by
The problem
Heart failure is a leading cause of morbimortality worldwide.
Current treatments manage symptoms and slow progression, but fail to repair or regenerate damaged myocardium. With an aging population, the clinical and economic burden keeps growing.
people affected by heart failure globally
of cases originate from ischemic events like myocardial infarction
of patients die within five years of diagnosis
Our solution
Heart regeneration.
We are developing a first-in-class, injectable regenerative therapy designed to repair the heart after myocardial infarction. It is delivered directly into the damaged cardiac tissue during existing procedures, where it helps restore function and limit long-term damage.
Unlike current treatments that only slow disease progression, our approach aims to address the root cause by repairing the injured heart tissue.
Current treatments
- Manage symptoms
- Slow progression
Amnova
- Repairs tissue
- Targets the root cause
What happens to the heart after a heart attack
Drag to explore
The blocked artery starves part of the heart muscle of oxygen. Cells in that area die within hours.
Moving forward
From the lab to patients.
If you work in cardiology, do research, invest or tell science stories in the media, we'd like to meet you.
Technology
An injectable regenerative biomaterial.
02
Scalable
We translate these biological principles into a practical, scalable therapy designed for real-world clinical use.
03
Minimally invasive
Delivered during existing cardiac procedures, with no additional surgery.
In the hospital
How the treatment is administered.
Our therapy is designed to fit into the care a heart attack patient already receives, with no additional surgery.
The patient is treated for the heart attack
After a myocardial infarction, the patient undergoes the standard procedure to reopen the blocked artery and restore blood flow.
The therapy is injected into the damaged area
During that same procedure, the injectable biomaterial is delivered directly into the injured cardiac tissue.
The tissue begins to regenerate
The biomaterial creates an environment that supports the repair of the damaged muscle, helping restore function and limit long-term damage.
Amnova's therapy is under development and is not yet available for clinical use.
Roadmap
From the lab to the clinic.
The path every new therapy must follow before reaching patients.
- 1Development
First version of the hydrogel
Initial formulation of the injectable biomaterial.
- 2Development
Optimized version
Refining composition, handling and injectability.
- 3Development
Bioinformatic and in vitro studies
Characterizing the biological activity of the therapy in the lab.
- 4Development
Animal studies
Evaluating safety and efficacy in preclinical models of myocardial infarction.
- 5Regulatory
Regulatory process (FDA)
Submitting the preclinical package to obtain authorization for human trials.
- 6Clinical
Phase I clinical trials
First studies in patients, focused on safety.
- 7Clinical
Phase II clinical trials
Evaluating efficacy and the optimal dose in a larger group of patients.
- 8Clinical
Phase III clinical trials
Large-scale confirmation of benefit ahead of approval.
Want to be part of the next stage?
Awards & recognition
Recognized by institutions that believe in science.
2026START Fellowship x Inspired
Winners
2025
Competencia de Startups · Universidad de San Andrés
Winners in Biotechnology
2026
En la primera edición del Swiss Innovation Day en Argentina
We are winners of the startup competition.
2025
Premio César Milstein · CONICET
Special mention · Biotechnology research with impact on health
2025
eAwards Argentina (E-World)
Finalists · Technology startups with impact on health
2025
IncuBAte · Ciudad de Buenos Aires
Selected for the incubation programme
In their words
Interviews and conversations about what we do.
Selected talks with our founders and scientists.
News
Latest from Amnova.
Press coverage and updates from our team.
Contact
Let's talk.
Patients, physicians, investors, press or future teammates: tell us who you are and we'll take it from there.